The combination of CD44, CD133, and VDR as potential diagnostic markers in ovarian cancer is supported by their roles in cancer stem cell biology, their association with aggressive tumor characteristics, and their influence on clinical outcomes. This evidence concerns the gene PROM1 and ovarian carcinoma.